Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABAR...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fernández, Marisa Liliana, Marson, María Elena, Ramírez, Juan Carlos, Mastrantonio Garrido, Guido Enrique, Schijman, Alejandro Gabriel, Altcheh, Jaime, Riarte, Adelina Rosa, García Bournissen, Facundo
Formato: Articulo
Lenguaje:Inglés
Publicado: 2016
Materias:
Biología
Benznidazole
Chagas disease
Pharmacology
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/86271
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
Descripción
Sumario:Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.

Ejemplares similares